Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [21] Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer
    Adelstein, DJ
    Rice, TW
    Rybicki, LA
    Greskovich, JF
    Ciezki, JP
    Carroll, MA
    DeCamp, MM
    LUNG CANCER, 2002, 36 (02) : 167 - 174
  • [23] From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer
    Jeremic, Branislav
    Milicic, Biljana
    CANCER, 2008, 112 (04) : 876 - 884
  • [24] Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer
    Wang, GM
    Song, MF
    Xu, HY
    Fang, Y
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02): : 309 - 313
  • [25] Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer
    Keene, KS
    Harman, EM
    Knauf, DG
    McCarley, D
    Zlotecki, RA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (03): : 217 - 222
  • [26] RADIOTHERAPY AND CHEMOTHERAPY FOR INOPERABLE NONSMALL CELL LUNG-CANCER
    BLEASDALE, C
    JONES, B
    POSTGRADUATE MEDICAL JOURNAL, 1995, 71 (837) : 393 - 396
  • [27] Concurrent accelerated hyperfractionation radiotherapy and chemotherapy for stage III non-small cell lung cancer.
    Hitoshi, Y
    Toshiaki, T
    Noriko, H
    Tetsuro, T
    Kazoro, I
    Etsuko, T
    Teruhiko, I
    Yoshiaki, S
    Hideaki, O
    Satoshi, F
    Fumiaki, U
    Hajime, O
    Hideo, U
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 315 - 315
  • [28] Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer
    Machtay, M
    Washam, C
    Devine, P
    SEMINARS IN ONCOLOGY, 2005, 32 (02) : S9 - S12
  • [29] Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients
    Werner-Wasik, M
    Scott, C
    Graham, ML
    Smith, C
    Byhardt, RW
    Roach, M
    Andras, EJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (02): : 327 - 331
  • [30] Feasibility of Image-Guided Radiotherapy and Concurrent Chemotherapy for Locally Advanced Nonsmall Cell Lung Cancer
    Nguyen, Nam P.
    Kratz, Sarah
    Chi, Alexander
    Vock, Jacqueline
    Vos, Paul
    Shen, Wei
    Vincent, Vinh-Hung
    Ewell, Lars
    Jang, Siyoung
    Altdorfer, Gabor
    Karlsson, Ulf
    Godinez, Juan
    Woods, William
    Dutta, Suresh
    Ampil, Fred
    CANCER INVESTIGATION, 2015, 33 (03) : 53 - 60